Merck Shares Face Headwinds as 2026 Forecast Dims

Merck issues 2026 guidance below 2025 results, citing generic competition for Mavenclad and currency headwinds. CEO Belén Garijo departs as shares fall sharply.

Investors in German pharmaceutical and specialty chemicals group Merck have been handed a sobering outlook for the coming fiscal year. The Darmstadt-based company has issued guidance for 2026 that falls below prior-year performance, citing competitive pressures on a key drug and adverse currency movements. This cautious stance has triggered a sharp sell-off in the company's equity.

Leadership Transition and Strategic Shifts

Adding a layer of uncertainty is a significant change in the executive suite. CEO Belén Garijo is set to depart in April, moving to rival firm Sanofi. Her successor will take the helm of an organization in the midst of strategic repositioning. To bolster its future growth pipeline, Merck recently deployed approximately $3.9 billion to acquire SpringWorks Therapeutics.

Despite these forward-looking investments, the immediate financial picture has darkened. The company's share price has reflected this anxiety, declining by over eleven percent in the past week to trade at €113.40.

Revised Financial Targets for 2026

Management now anticipates adjusted EBITDA for 2026 to land in a range of €5.5 billion to €6.0 billion. This represents a potential drop of nearly ten percent compared to the €6.1 billion reported for the previous year. Revenue projections tell a similar story, with guidance set between €20.0 billion and €21.1 billion. At the lower end, this would signify a decrease from the €21.1 billion in sales achieved in 2025.

Two primary factors are driving this constrained forecast. First, competition from generic versions of its multiple sclerosis treatment, Mavenclad, is expected to begin in the United States in March. Second, the company's earnings are being hurt by a weaker U.S. dollar; Merck generates roughly a quarter of its revenue in the American market.

2025 Performance Provides Mixed Backdrop

The revised outlook follows a year of relative operational stability. In 2025, Merck's business was supported primarily by demand for semiconductor chemicals and biotech equipment, enabling organic sales growth of 3.1 percent. Although post-tax profit contracted by six percent to around €2.6 billion, the company intends to maintain its dividend payout to shareholders at a steady €2.20 per share.

Technical Analysis and Potential Catalysts

From a chart perspective, the recent sharp decline has pushed the stock into deeply oversold territory, with its Relative Strength Index (RSI) reading at 22.6. Market technicians are now watching the 52-week low of €104.85 as a critical level of psychological support should the downward trend persist.

The coming months will determine whether this conservative guidance can be surpassed. Potential approvals for new products, such as the drug Pergoveris in the U.S., offer one avenue for a positive surprise. For now, however, Merck's near-term trajectory appears clouded by significant external challenges.